Lilly’s targeted RET drug shrinks tumours in lung cancer trial
Lilly’s drug, now called selpercatinib, is intended for patients with rare RET abnormalities, which occur in about 2 per cent of…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.